Bahrain to screen 6,000 children for blood disorders:
This article was originally published in Clinica
Bahrain is to begin its annual screening project of children aged between 25-16 for hereditary blood disorders. The project, which targets sufferers of sickle cell anaemia, beta thalassemia and Glucose-6-Phosphate Dehydrogenase deficiency, is funded by the Bahrain Society for Hereditary Diseases to the tune of BD20,000 ($53,000) and organised in collaboration with the ministry of health. This is the sixth time that such a screening project has been undertaken in Bahrain and, on its completion in May 2004, a total of 36,000 children will have been tested.
You may also be interested in...
As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.